Aerie Pharmaceuticals (NASDAQ: AERI) recently received a number of ratings updates from brokerages and research firms:

  • 12/5/2017 – Aerie Pharmaceuticals was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 11/22/2017 – Aerie Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “With no approved product in its portfolio, Aerie depends heavily on a potential approval of Rhopressa. Aerie had to withdraw its NDA in the United States submitted in 2016 as a third-party manufacturing facility in Tampa, FL, not being ready for pre-approval inspection. The delay in the NDA filing was quite disappointing as Rhopressa is Aerie’s lead late-stage candidate. Any such delays will adversely impact prospects. Aerie resubmitted its NDA for lead candidate Rhopressa in Feb 2017. The FDA determined that the application is sufficiently complete to permit a substantive review and set the PDUFA goal date for the completion of review as Feb 28, 2018. The Dermatologic and Ophthalmic Drugs Advisory Committee of the FDA voted in favor of Rhopressa’s approval. A potential approval of Rhopressa will boost the company’s growth prospects. Aerie’s shares have outperformed the industry in the last six months.”
  • 11/16/2017 – Aerie Pharmaceuticals was given a new $73.00 price target on by analysts at Canaccord Genuity. They now have a “buy” rating on the stock.
  • 11/16/2017 – Aerie Pharmaceuticals was given a new $69.00 price target on by analysts at Cantor Fitzgerald. They now have a “buy” rating on the stock.
  • 11/9/2017 – Aerie Pharmaceuticals had its “buy” rating reaffirmed by analysts at Mizuho. They now have a $87.00 price target on the stock. They wrote, “We do not view quarterly earnings as an important performance measure of companies like Aerie as valuation is primarily driven by progress of the R&D pipeline.””
  • 11/3/2017 – Aerie Pharmaceuticals had its “buy” rating reaffirmed by analysts at Mizuho.
  • 10/25/2017 – Aerie Pharmaceuticals had its “buy” rating reaffirmed by analysts at Mizuho. They now have a $70.00 price target on the stock.
  • 10/24/2017 – Aerie Pharmaceuticals was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Aerie’s efforts on developing two late-stage candidates – Rhopressa and Roclatan – are encouraging. The company resubmitted new drug application (NDA) for lead candidate Rhopressa in Feb 2017. The FDA determined that the application is sufficiently complete to permit a substantive review and set the PDUFA goal date for the completion of review as Feb 28, 2018. Earlier in the month, the Dermatologic and Ophthalmic Drugs Advisory Committee of the FDA voted in favor of Rhopressa’s approval. A potential approval of Rhopressa in early 2018 and successful commercialization will significantly boost the company’s growth prospects in the global ophthalmic market. Aerie’s shares have outperformed the industry in the year so far. However, with no approved product in its portfolio, Aerie depends heavily on a potential approval of Rhopressa. A further delay will impact the growth prospects.”
  • 10/23/2017 – Aerie Pharmaceuticals is now covered by analysts at Guggenheim. They set a “buy” rating and a $80.00 price target on the stock.
  • 10/16/2017 – Aerie Pharmaceuticals had its “positive” rating reaffirmed by analysts at Canaccord Genuity. They now have a $73.00 price target on the stock, up previously from $65.00.
  • 10/16/2017 – Aerie Pharmaceuticals had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $76.00 price target on the stock, up previously from $65.00.
  • 10/16/2017 – Aerie Pharmaceuticals had its “buy” rating reaffirmed by analysts at Mizuho. They now have a $70.00 price target on the stock. They wrote, “We expect an approval on or prior to the PDUFA date.””
  • 10/11/2017 – Aerie Pharmaceuticals was given a new $68.00 price target on by analysts at JMP Securities. They now have a “buy” rating on the stock.
  • 10/11/2017 – Aerie Pharmaceuticals was given a new $65.00 price target on by analysts at Canaccord Genuity. They now have a “buy” rating on the stock.
  • 10/11/2017 – Aerie Pharmaceuticals had its “buy” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $62.00 price target on the stock.
  • 10/10/2017 – Aerie Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Aerie’s efforts on developing two late-stage candidates – Rhopressa and Roclatan – are encouraging. However, with no approved product in its portfolio, Aerie depends heavily on a potential approval of Rhopressa. The company resubmitted new drug application (NDA) for lead candidate Rhopressa in Feb 2017. The FDA determined that the application is sufficiently complete to permit a substantive review and set the PDUFA goal date for the completion of review as Feb 28, 2018. A further delay will impact the growth prospects. A meeting of the Dermatologic and Ophthalmic Drugs Advisory Committee of the FDA has been scheduled for October 13 to review the NDA. A potential approval of Rhopressa in early 2018 and successful commercialization will significantly boost the company’s growth prospects in the global ophthalmic market. Aerie’s shares performed worse than the industry in the last three months.”

Aerie Pharmaceuticals Inc (NASDAQ AERI) traded down $2.50 during trading on Wednesday, hitting $58.90. 282,900 shares of the stock were exchanged, compared to its average volume of 512,570. Aerie Pharmaceuticals Inc has a twelve month low of $35.50 and a twelve month high of $66.60. The company has a current ratio of 15.24, a quick ratio of 15.24 and a debt-to-equity ratio of 0.78.

Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan).

Receive News & Ratings for Aerie Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.